Whanin Pharm환인제약
016580 · KOSPI · ₩016580 · 환인제약
₩10,230▲ ₩150 (1.49%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩255B | ₩260B | ₩230B | ₩199B | ₩178B |
| Cost of sales | ₩168B | ₩166B | ₩131B | ₩100B | ₩84B |
| Gross profit | ₩87B | ₩94B | ₩99B | ₩99B | ₩93B |
| Operating income | ₩13B | ₩21B | ₩30B | ₩30B | ₩31B |
| Net income | ₩14B | ₩23B | ₩30B | ₩24B | ₩26B |
| Net income to shareholders | ₩14B | ₩23B | ₩30B | ₩24B | ₩27B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩479B | ₩425B | ₩401B | ₩369B | ₩353B |
| Current assets | ₩228B | ₩201B | ₩212B | ₩197B | ₩242B |
| Cash and equivalents | ₩64B | ₩43B | ₩45B | ₩37B | ₩64B |
| Total liabilities | ₩58B | ₩49B | ₩43B | ₩35B | ₩36B |
| Current liabilities | ₩57B | ₩42B | ₩40B | ₩32B | ₩31B |
| Borrowings | ₩2B | ₩1.7B | ₩1.7B | ₩1.7B | ₩1.7B |
| Total equity | ₩421B | ₩376B | ₩358B | ₩334B | ₩317B |
| Shareholders' equity | ₩421B | ₩376B | ₩358B | ₩334B | ₩317B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩9B | ₩21B | ₩23B | ₩17B | ₩35B |
| Free cash flow | ₩9B | ₩21B | ₩23B | ₩17B | ₩35B |
| Dividends paid | ₩4.6B | ₩4.6B | ₩4.6B | ₩4.6B | ₩4.6B |
Consolidated where available. Amounts in won.
Also known as: Whanin Pharm / 환인제약 / 016580 / KRX:016580
Source: KRX statistical information